Clinical Trial Update: Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Sarcomatoid Carcinoma

Drugs mentioned

• Imfinzi (durvalumab) (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: HNSCC, Head and Neck Neoplasms | Phase 2 | Status: COMPLETED